Business
MYCR: Q2 delivered robust sales and EBIT growth, offset by lower order intake and active M&A
MYCR: Q2 delivered robust sales and EBIT growth, offset by lower order intake and active M&A
About this update from Mycronic Ab
Q2 saw 35% sales growth and a 27% EBIT margin, with strong performance in Pattern Generators and High Volume, but order intake declined due to no new system orders. Three acquisitions and a share split were completed, and full-year sales guidance was reaffirmed at SEK 7.5 billion. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.